

Molecular and Cellular Biomedical Sciences

Volume 3, Number 2, September 2019

REVIEW ARTICLES

Adiponectin and Its Role in Inflammatory Process of Obesity

Ami Febriza, Ridwan, Suryani As'ad, Vivien Novarina Kasim, Hasta Handayani Idrus; p.60-6

RESEARCH ARTICLES

Antioxidant, α -Glucosidase Inhibitory Activity and Molecular Docking Study of Gallic Acid, Quercetin and Rutin: A Comparative Study

Agus Limanto, Adelina Simamora, Adit Widodo Santoso, Kris Herawan Timotius; p.67-74

A Comparison of Osteoblast Cell Proliferation and Osteocalcin Expression in Cuttlefish Bone and Bovine Bone Xenograft

Komang Agung Irianto, Ameria Pribadi, Ilham Abdullah Irsyam, Yudhistira Pradnyan Klopung, Oen Sindrawati; p.75-80

Drug-Herb Interaction between Metformin and *Momordica charantia* in Diabetic Mice

Asri Dwi Endah Dewi Pramesthi, Mirhansyah Ardana, Niken Indriyanti; p.81-7

Association between Hasford Scoring System and Hematologic Response in Chronic and Accelerated Phase of Chronic Myelocytic Leukemia Patient with Imatinib for Three Months

Andy Purnomo, Ugroseno Yudho Bintoro, Made Putra Sedana, Ami Ashariati; p.88-94

The Difference of Bax Protein Expression between Endometrioma and Ovarian Carcinoma

Chandran Frinaldo Saragih, Riza Rivany, Mohamad Fauzie Sahil, Fadjrir, Edy Ardiansyah, Muhammad Rizki Yaznil, Munauwarus Sarirah; p.95-9

Antioxidant Effects of Red Fruit Oil on MMP-1 Gene Expression and Malondialdehyde Levels on Skin Exposed to UVB Rays

Monita Sugianto, Achadiyani, Gaga Irawan Nugraha; p.100-6

Sugar Palm Fruits (*Arenga pinnata*) as Potential Analgesics and Anti-Inflammatory Agent

Evi Sovia, Dian Anggraeny; p.107-4

The Effect of *Myrmecodia pendans* Ethanol Extract on Inflamed Pulp: Study on Sprague Dawley Rats

Janti Sudiono, Meylisa Hardina; p.115-21

Chemical Constituents of Snake Fruit (*Salacca zalacca* (Gaert.) Voss) Peel and *in silico* Anti-aging Analysis

Ermi Girsang, I Nyoman Ehrich Lister, Chrismis Novalinda Ginting, Adrian Khu, Butter Samin, Wahyu Widowati, Satrio Wibowo, Rizal Rizal; p.122-8

Print ISSN: 2527-4384

Online ISSN: 2527-3442

<https://www.cellbiopharm.com/ojs/index.php/MCBS>

Cell and
Biopharmaceutical
Institute



Molecular and Cellular Biomedical Sciences

PRINCIPAL CONTACT

MCBS OFFICE
Prodia Tower 8F, Jl. Kramat Raya No.150, Jakarta Pusat 10430
Email: mcbs_office@cellbiopharm.com

SUPPORT CONTACT

Nurrani Mustika Dewi
Email: nurranimustika@gmail.com

EDITOR IN CHIEF

Dr. Anna Meiliana
Postgraduate Program in Clinical Pharmacy, Faculty of Pharmacy,
Padjadjaran University, Indonesia

EDITORIAL BOARD

Prof. Akihiro Shimosaka
Hematology Institute, Peking Union Medical College, China

Prof. Anak Iamaroon
Department of Oral Biology and Diagnostic Sciences,
Faculty of Dentistry, Chiang Mai University, Thailand

Dr. Bin Ren
Division of Hematology and Oncology, Department of Medicine,
Medical College of Wisconsin, United States of America

Prof. Hee Young Shin
Department of Pediatrics, Cancer Research Institute,
Seoul National University College of Medicine, South Korea

Prof. Hiroyuki Kumamoto
Division of Oral Pathology, Department of Oral Medicine and Surgery,
Graduate School of Dentistry, Tohoku University, Japan

Dr. Ines Atmosukarto
College of Medicine, Biology & Environment,
Australian National University, Australia

Dr. Irawan Satriotomo
Center for Translational Research in Neurodegenerative Disease (CTRND),
University of Florida, United States of America

Dr. Laifa Annisa Hendamin
Section of Biology, Faculty of Medicine and Health Sciences,
Syarif Hidayatullah State Islamic University, Indonesia

Dr. Mutsumi Miyauchi
Department of Oral and Maxillofacial Pathobiology, Basic Life Sciences,
Institute of Biomedical and Health Sciences, Hiroshima University, Japan

Dr. Thai Yen Ling
Department of Pharmacology,
College of Medicine, National Taiwan University, Taiwan

Dr. Wahyu Widowati
Department of Biology,
Faculty of Medicine, Maranatha Christian University, Indonesia

Prof. Yen Hua Huang
Department of Biochemistry and Molecular Cell Biology,
Graduate Institute of Medical Sciences College of Medicine,
Taipei Medical University, Taiwan

Dr. Yudi Her Oktaviano
Department of Cardiology and Vascular Medicine,
Faculty of Medicine / Dr. Soetomo Hospital, Airlangga University, Indonesia

FOCUS AND SCOPE

Molecular and Cellular Biomedical Sciences (MCBS) is an open access, peer-reviewed journal that supports all topics in Biology, Pathology, Pharmacology, Biochemistry, Histology and Biomedicine in the aspect of molecular and cellular.

MCBS is dedicated to publish review and research articles. The editors will carefully select manuscript to be delivered for peer-reviewing process. Therefore MCBS is committed to present only the valuable and recent scientific findings.

SECTION POLICIES

REVIEW ARTICLE
Review Article should consist of no more than 10,000 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 200 references.

RESEARCH ARTICLE
Research Article should consist of no more than 3,500 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 40 references.

PEER REVIEW PROCESS

All manuscripts submitted to Molecular and Cellular Biomedical Sciences will be selected and blind peer-reviewed by 2 or more reviewers when necessary, to present valuable and authentic findings. All details will also be reviewed, including appropriate title; content reflecting abstract; concise writing; clear purpose, study method and figures and/or tables; and summary supported by content. The reviewing process will take generally 2-3 months depends on sufficiency of information provided.

Peer-reviewers were selected based on their specialties that fit to the topic. Additional reviewer/s can also be pointed when necessary. Author can suggest reviewer/s that not having publication together within five years and should not be member/s of the same research institution.

PUBLICATION FREQUENCY

Molecular and Cellular Biomedical Sciences is published biannually (in March and September).

OPEN ACCESS POLICY

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

ARCHIVING

This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration.

PLAGIARISM SCREENING POLICY

All manuscripts submitted to Molecular and Cellular Biomedical Sciences will be screened for plagiarism by using Grammarly.

Molecular and Cellular Biomedical Sciences

CONTENT LICENSING

All materials are free to be copied and redistributed in any medium or format. However, appropriate credit should be given. The material may not be used for commercial purposes. This content licensing is in accordance with a CC license: CC-BY-NC

CONFLICT OF INTEREST POLICY

AUTHOR'S CONFLICT OF INTEREST

At the point of submission, Molecular and Cellular Biomedical Sciences requires that each author reveal any personal and/or financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated. When considering whether you should declare a conflicting interest or connection, please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it? Corresponding authors are responsible to confirm whether they or their co-authors have any conflicts of interest to declare, and to provide details of these. The statement includes any information regarding whether the manuscript is under consideration for other publication, or whether you have any patents that relevant to the manuscript. If the manuscript is published, any conflict of interest information will be written in the Conflict of Interest statement.

AUTHOR'S ACKNOWLEDGEMENT

Authors whose manuscripts are submitted for publication must declare all relevant sources of funding in support of the preparation of a manuscript. Molecular and Cellular Biomedical Sciences requires full disclosure of financial support as to whether it is from government agencies, the pharmaceutical or any other industry, or any other source. Authors are required to specify sources of funding for the study and to indicate whether or not the manuscript was reviewed by the sponsor prior to submission. This information should be included in the Acknowledgements section of the manuscript. In addition to disclosure of direct financial support to the authors or their laboratories and prior sponsor-review of the paper, corresponding authors will be asked to disclose all relevant consultancies since the views expressed in the contribution could be influenced by the opinions they have expressed privately as consultants. This information should also be included in the Acknowledgments section of the manuscript.

REVIEWER'S CONFLICT OF INTEREST

Reviewers must disclose to editors any conflicts of interest that could bias their opinions of the manuscript, and should recuse themselves from reviewing specific manuscripts if the potential for bias exists. As in the case of authors, silence on the part of reviewers concerning potential conflicts may mean either that such conflicts exist that they have failed to disclose, or that conflicts do not exist. Reviewers must not use information of the manuscript they are reviewing before it is being published, to further their own interests.

PROTECTION OF HUMAN SUBJECT AND ANIMAL IN RESEARCH POLICY

When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the World Medical Association Declaration of Helsinki. If doubt exists whether the research was conducted in accordance with the said declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed. Further guidance on animal research ethics is available from the International Association of Veterinary Editors' Consensus Author Guidelines on Animal Ethics and Welfare.

INFORMED CONSENT POLICY

Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or

guardian) gives written informed consent for publication. Authors should disclose to these patients whether any potential identifiable material might be available via internet as well as in print after publication. Nonessential identifying details should be omitted.

Molecular and Cellular Biomedical Sciences decides that patient confidentiality is better guarded by having the authors archive the consent, and instead providing us with a written statement in the manuscript attesting that they have received and archived written patient consent. When informed consent has been obtained, it should be indicated later in the published article.

ROLE OF JOURNAL EDITOR

Editors of Molecular and Cellular Biomedical Sciences have responsibilities toward the authors who provide the content of the journals, the peer reviewers who comment on the suitability of manuscripts for publication, also toward the journal's readers and the scientific community. Editors are responsible for monitoring and ensuring the fairness, timeliness, thoroughness, and civility of the peer-review and other editorial processes.

Peer review by external reviewers with the proper expertise is the most common method to ensure manuscript quality. However, our editors may sometimes reject manuscripts without external peer review to make the best use of their resources. Reasons for this practice are usually that the manuscript is outside the scope of Molecular and Cellular Biomedical Sciences, does not meet our quality standards or lacks originality or novel information.

Editor Responsibilities toward Authors

- Providing guidelines to authors for preparing and submitting manuscripts
- Providing a clear statement of the Journal's policies on authorship criteria
- Treating all authors with fairness, courtesy, objectivity, honesty, and transparency
- Establishing and defining policies on conflicts of interest for all involved in the publication process, including editors, staff, authors, and reviewers
- Protecting the confidentiality of every author's work
- Establishing a system for effective and rapid peer review
- Making editorial decisions with reasonable speed and communicating them in a clear and constructive manner
- Being vigilant in avoiding the possibility of editors and/or referees delaying a manuscript for suspect reasons
- Establishing a procedure for reconsidering editorial decisions
- Describing, implementing, and regularly reviewing policies for handling ethical issues and allegations or findings of misconduct by authors and anyone involved in the peer review process
- Informing authors of solicited manuscripts that the submission will be evaluated according to the journal's standard procedures or outlining the decision-making process if it differs from those procedures
- Clearly communicating all other editorial policies and standards

Editor Responsibilities toward Reviewers

- Assigning papers for review appropriate to each reviewer's area of interest and expertise
- Establishing a process for reviewers to ensure that they treat the manuscript as a confidential document and complete the review promptly
- Informing reviewers that they are not allowed to make any use of the work described in the manuscript or to take advantage of the knowledge they gained by reviewing it before publication
- Providing reviewers with written, explicit instructions on the journal's expectations for the scope, content, quality, and timeliness of their reviews to promote thoughtful, fair, constructive, and informative critique of the submitted work
- Requesting that reviewers identify any potential conflicts of interest and asking that they recuse themselves if they cannot provide an unbiased review
- Allowing reviewers appropriate time to complete their reviews
- Requesting reviews at a reasonable frequency that does not overtask any reviewer
- Finding ways to recognize the contributions of reviewers, for example, by publicly thanking them in the journal; providing letters that might be used in applications for academic promotion; offering professional education credits; or inviting them to serve on the editorial board of the journal
- Making final decision regarding a submission status after receiving review result from reviewers

Molecular and Cellular Biomedical Sciences

Editor Responsibilities toward Readers and the Scientific Community

- Evaluating all manuscripts considered for publication to make certain that each provides the evidence readers need to evaluate the authors' conclusions and that authors' conclusions reflect the evidence provided in the manuscript
- Providing literature references and author contact information so interested readers may pursue further discourse
- Requiring the corresponding author to review and accept responsibility for the content of the final draft of each paper
- Maintaining the journal's internal integrity (e.g., correcting errors; clearly identifying and differentiating types of content, such as reports of original data, corrections/errata, retractions, supplemental data, and promotional material or advertising; and identifying published material with proper references)
- Ensuring that all involved in the publication process understand that it is inappropriate to manipulate citations by, for example, demanding that authors cite papers in the journal
- Disclosing all relevant potential conflicts of interest of those involved in considering a manuscript or affirming that none exist
- Working with the publisher to attract the best manuscripts and research that will be of interest to readers

AUTHOR GUIDELINES

1. General Terms

Molecular and Cellular Biomedical Sciences welcomes articles covering all aspects of biomedical sciences. All submitted manuscripts must not be previously published and not under consideration for publication elsewhere. Papers may come from any country but must be written in English. The manuscript may be submitted as review articles, research articles, and short communications. There are no submission and processing charges for this journal.

All manuscripts are subjected to peer review. All submissions must be accompanied by abstracts of the authors' manuscripts on related subjects that are in press or under editorial review. Electronic reprints of related published papers by the author/s or manuscripts in the press also may be helpful to the reviewers.

All manuscripts must be accompanied by a covering letter signed by all author/s. Upon acceptance, author/s must transfer copyright to Cell and BioPharmaceutical Institute (CBPI). Accepted papers become the permanent property of CBPI and may be used according to copyright policy, or for particular purposes, please contact CBPI. It is the author/s' responsibility to obtain permission to reproduce illustrations, tables, etc. from other publication.

2. How to Submit

Authors are required to submit manuscripts electronically by using online journal system cellbiopharm.com/ojs.

3. Requirements of Each Manuscript Type

Review Article: Review Article should consist of no more than 10,000 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 200 references.

Research Article: Research Article should consist of no more than 3,500 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 40 references.

4. Abstract

Provide an abstract of no more than 300 words (for Review Article) or 250 words (for Research Article). Structured-abstract should be followed in writing Research Article.

5. References

- References should be according to the Vancouver system.
- List all authors when there are six or fewer; when there are seven or more, list the first six, followed by "et al."
- A sequential number of references in the main text. Please follow in detail all examples below:

Article:

Sandra F, Esposti MD, Ndebele K, Gona P, Knight D, Rosenquist M, et al. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Alters Mitochondrial Membrane Lipids. *Cancer Res.* 2005; 65(18): 8286-97.

Book

Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. *Medical microbiology*. 4th ed. St. Louis: Mosby; 2002.

Chapter in a book:

Rosenberg GA. Matrix metalloproteinase and proteolytic opening of the blood-brain-barrier in neuroinflammation. In: deVries E, Prat A, editors. *The Blood-brain Barrier and Its Microenvironment Basic Physiology To Neurological Disease*. New York: Taylor and Francis Group; 2005. p.335-58.

Dissertation/Thesis/Essay:

Arlaukas SP. Near infrared fluorescent choline kinase alpha inhibitors for cancer imaging and therapy [Dissertation]. Philadelphia: University of Pennsylvania; 2015.

Part of Website/Monograph:

Medline Plus [Internet]. Bethesda: US National Library of Medicine; ©2009. Diabetic Kidney Problems [update 2015 Nov 2; cited 2015 Nov 16]. Available from: <https://www.nlm.nih.gov/medlineplus/diabetickidneyproblems.html>.

Conference Paper:

Fledelius HS. Myopia and significant visual impairment: global aspects. In: Lin LLK, Shin YF, Hung PT, editors. *Myopia Updates II: Proceedings of the 7th International Conference on Myopia 1998 Nov 17-20, Taipei*. Tokyo: Springer; 2000. p.3-17.

6. Unit of Measurement

- Authors can express all measurements in Conventional or International System (SI) units.
- Drug names must use generic names. When proprietary brands are used in research, include the brand name, the name and location (city & country) of the manufacturer in parentheses after the first mention of the generic name.

SUBMISSION PREPARATION CHECKLIST

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
2. The submission file is in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format. Formatted as standard A4 page setup.
3. Where available, URLs for the references have been provided.
4. The text should be double-spaced with the 1-inch margin on the left and right sides. Use 12-point Times New Roman font.
5. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.
6. Running title provided (not more than 8 words).
7. Proof of permission was obtained to reproduce illustrations, tables, etc. from other publication.
8. Complete information about author/s (first, middle, last name), author/s's affiliation, and email address of the corresponding author.
9. All pages are numbered at bottom right.

COPYRIGHT NOTICE

For the submission of a manuscript to Molecular and Cellular Biomedical Sciences, I hereby certify that:

1. I have been granted authorization by my co-author/s to enter into these arrangements.
2. I hereby declare, on behalf of myself and my co-author/s, that:
 - The manuscript submitted is an original work and has neither been published in any other peer-reviewed journal nor is under consideration for publication by any other journal. More so, the work has been carried out in the author/s' lab and the manuscript does not contravene any existing copyright or any other third party rights.
 - I am/we are the sole author/s of the manuscript and maintain the authority to enter into this agreement and the granting of rights to the publisher: The Cell and BioPharmaceutical Institute (CBPI), does not infringe any clause of this agreement.
 - The manuscript contains no such material that may be unlawful,

Molecular and Cellular Biomedical Sciences

defamatory, or which would, if published, in any way whatsoever, violate the terms and conditions as laid down in the agreement.

- I/we have taken due care that the scientific knowledge and all other statements contained in the manuscript conform to true facts and authentic formulae and will not, if followed precisely, be detrimental to the user.
- I/we permit the adaptation, preparation of derivative works, oral presentation or distribution, along with the commercial application of the work.
- No responsibility is assumed by Molecular and Cellular Biomedical Sciences (MCBS) and CBPI, its staff or members of the editorial boards for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in a publication by MCBS.

Copyright:

Author/s who publish in any MCBS print & online journal will transfer copyright to their work to CBPI. Submission of a manuscript to the respective journals implies that all author/s have read and agreed to the content of the Covering Letter or the Terms and Conditions. It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the manuscript for publication the author/s agree that the publishers have the legal right to take appropriate action against the author/s, if plagiarism or fabricated information is discovered. By submitting a manuscript, the author/s agree that the copyright of their manuscript is transferred to CBPI, if and when the manuscript is accepted for publication. Once submitted to the journal, the author/s will not withdraw their manuscript at any stage prior to publication. However, the copyright will be released to author/s when the manuscript is rejected.

Molecular and Cellular Biomedical Sciences

CONTENT

REVIEW ARTICLES

Adiponectin and Its Role in Inflammatory Process of Obesity

Ami Febriza, Ridwan, Suryani As'ad, Vivien Novarina Kasim, Hasta Handayani Idrus

p.60-6

RESEARCH ARTICLES

Antioxidant, α -Glucosidase Inhibitory Activity and Molecular Docking Study of Gallic Acid, Quercetin and Rutin: A Comparative Study

Agus Limanto, Adelina Simamora, Adit Widodo Santoso, Kris Herawan Timotius

p.67-74

A Comparison of Osteoblast Cell Proliferation and Osteocalcin Expression in Cuttlefish Bone and Bovine Bone Xenograft

Komang Agung Irianto, Ameria Pribadi, Ilham Abdullah Irsyam, Yudhistira Pradnyan Kloping, Oen Sindrawati

p.75-80

Drug-Herb Interaction between Metformin and *Momordica charantia* in Diabetic Mice

Asri Dwi Endah Dewi Pramesthi, Mirhansyah Ardana, Niken Indriyanti

p.81-7

Association between Hasford Scoring System and Hematologic Response in Chronic and Accelerated Phase of Chronic Myelocytic Leukemia Patient with Imatinib for Three Months

Andy Purnomo, Ugroseno Yudho Bintoro, Made Putra Sedana, Ami Ashariati

p.88-94

The Difference of Bax Protein Expression between Endometrioma and Ovarian Carcinoma

Chandran Frinaldo Saragih, Riza Rivany, Mohamad Fauzie Sahil, Fadjrir, Edy Ardiansyah, Muhammad Rizki Yaznil, Munauwarus Sarirah

p.95-9

Antioxidant Effects of Red Fruit Oil on MMP-1 Gene Expression and Malondialdehyde Levels on Skin Exposed to UVB Rays

Monita Sugianto, Achadiyani, Gaga Irawan Nugraha

p.100-6

Sugar Palm Fruits (*Arenga pinnata*) as Potential Analgesics and Anti-Inflammatory Agent

Evi Sovia, Dian Anggraeny

p.107-4

The Effect of *Myrmecodia pendans* Ethanol Extract on Inflamed Pulp: Study on Sprague Dawley Rats

Janti Sudiono, Meylisa Hardina

p.115-21

Chemical Constituents of Snake Fruit (*Salacca zalacca* (Gaert.) Voss) Peel and *in silico* Anti-aging Analysis

Ermir Girsang, I Nyoman Ehrich Lister, Chrismis Novalinda Ginting, Adrian Khu, Butter Samin, Wahyu Widowati,

Satrio Wibowo, Rizal Rizal

p.122-8

Molecular and Cellular Biomedical Sciences

Abstract

DDC 616.398

Febriza A, Ridwan, As'ad S, Kasim VN, Idrus HH (Department of Physiology, Faculty of Medicine, Universitas Muhammadiyah Makassar, Makassar, Indonesia)

Adiponectin and Its Role in Inflammatory Process of Obesity

Mol Cell Biomed Sci. 2019; 3(2): 60-6

Abstract (English)

Obesity is a chronic, low degree systemic inflammatory status. Microarray examination shows a disturbance in the expression of cytokine, chemokine, complementary protein and half of the other acute phase components in obese patients. Adiponectin is the hormone that increases insulin sensitivity, while its level decreases under condition of fatty tissue enlargement that occurs in obesity. Excessive weight causes the adipocyte cells and adipose tissues produce various types of mediators. The inflammatory process is the main cause of metabolic diseases, and the main role of adipose tissue in the inflammatory process is determined by the production of pro-inflammatory mediators and anti-inflammatory mediators. Adiponectin has an important anti-inflammatory effect on obesity. Adiponectin has an important anti-inflammatory effect on obesity. Adiponectin works on macrophage and monocyte to inhibit the production of pro-inflammatory cytokine and increase the expression of interleukin (IL)-10 and IL-1 receptor antagonists. Adiponectin reduces induction of intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 endothelial adhesion by TNF- α or resistin. In obese patients, it is characterized by resistance to adiponectin alongside a decrease and the possibility of adiponectin loss in the receptor population in liver and muscles, leading to low adiponectin level.

Keywords: adiponectin, obesity, inflammation

DDC 613.286

Limanto A, Simamora A, Santoso AW, Timotius KH (Department of Biochemistry, Krida Wacana Christian University, Jakarta, Indonesia)

Antioxidant, α -Glucosidase Inhibitory Activity and Molecular Docking Study of Gallic Acid, Quercetin and Rutin: A Comparative Study

Mol Cell Biomed Sci. 2019; 3(2): 67-74

Abstract (English)

Background: Plant-phenolics and flavonoids, including gallic acid, quercetin and rutin, are considered as safe inhibitors for α -glucosidase. This study aimed to compare antioxidant and α -glucosidase inhibitory activities of gallic acid (GA), quercetin (QUE) and rutin (RUT).

Materials and Methods: Pure compounds of GA, QUE, and RUT were used. Their antioxidant and inhibitory activity on α -glucosidase were investigated spectroscopically, including their kinetic analysis and interaction mechanism by docking simulation.

Results: All the tested compounds (GA, QUE, and RUT) showed good antioxidant activity better than the standards ascorbic acid (AA) and butylated hydroxytoluene (BHT), with QUE showing the highest antioxidant activity based on 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity. Based on their reducing properties, the activities of the compounds follow the following order: AA > GA > BHT > QUE > RUT. Both GA and RUT induced a competitive type of inhibition, with activities stronger than acarbose ($IC_{50} = 823 \mu\text{g/mL}$), whereas QUE inhibited in a mixed type manner. The IC_{50} of GA, QUE, and RUT were 220.12, 65.52, and 224.55 $\mu\text{g/mL}$ respectively. The results obtained from molecular docking indicate that all compounds have affinity in the active site pocket of α -glucosidase, with the hydrogen bond being the major force involved in each compound binding to the enzyme.

Conclusion: In conclusion, QUE has better antioxidant and α -glucosidase inhibitory activity than GA and RUT. This work provides insights into the interactions between GA, QUE, and RUT and α -glucosidase.

Keywords: docking, gallic acid, α -glucosidase, rutin, quercetin

DDC 573.76

Irianto KA, Pribadi A, Irsyam IA, Klopung YP, Sindrawati O (Dr. Soetomo General Hospital, Surabaya, Indonesia)

A Comparison of Osteoblast Cell Proliferation and Osteocalcin Expression in Cuttlefish Bone and Bovine Bone Xenograft

Mol Cell Biomed Sci. 2019; 3(2): 75-80

Abstract (English)

Background: Cuttlefish bone Xenograft, calcium phosphate (CaP)-based biomaterial graft, offers an alternative and has been accepted for osteoconductive and probable osteo-inductive attributes. This study aims to compare the bone healing potential between the bovine-derived (BHA) and cuttlefish bone-derived (CHA).

Materials and Methods: The study compared osteoblast cell proliferation of 27 New Zealand rabbits in 2.5 mm bone defect made in the femoral bone. The samples were divided into three groups, which were control, BHA and CHA group. The chemical and physical

Molecular and Cellular Biomedical Sciences

characteristics of BHA and CHA were determined for the content of hydroxyapatite by Fourier-Transform Infrared Spectroscopy (FTIR) and X-Ray Diffraction (XRD), then tested by Scanning Electron Microscopy (SEM) to evaluate the porosity. In the end of the second week, histopathologic and immunohistochemistry examinations were performed to evaluate the amount of osteoblast and osteocalcin expression.

Results: The FTIR, XRD and SEM analysis showed both BHA and CHA samples were hydroxyapatite according to Joint Committee on Powder Diffraction Standards (JCPDS). The CHA was significantly higher (297.22 ± 19.772) compared to BHA (258.22 ± 30.926) and control (131.67 ± 34.213). Osteocalcin expression in CHA (7.82 ± 2.230) compared to BHA (6.09 ± 3.724) and control (4.07 ± 3.606), was not significant ($p > 0.05$).

Conclusion: CHA group has the highest osteoblast cell proliferation and osteocalcin expression, meaning has a good potential as future source of bone graft.

Keywords: cuttlefish bone, bovine, bone graft, osteoblast cell

DDC 616.462

Pramesthi ADED, Ardana M, Indriyanti N (Research and Development Farmaka Tropis Laboratory, Faculty of Pharmacy, Universitas Mulawarman, Samarinda, Indonesia)

Drug-Herb Interaction between Metformin and *Momordica charantia* in Diabetic Mice

Mol Cell Biomed Sci. 2019; 3(2): 81-7

Abstract (English)

Background: Bitter melon has various metabolites, such as momordicosides, polypeptide-P, v-insulin, charantin, and vicine that have antidiabetic effect. It has synergistically effect while combined with oral diabetic drugs, such as metformin as glucose lowering agent. The aim of this study is to investigate the interaction of bitter melon fruit juice and metformin as glucose lowering agent in mice.

Materials and Methods: Alloxan-induced diabetic mice were treated with bitter melon fruit juice, metformin, and the combination of those two for 21 days. Glucose level was checked on first and last day of treatment.

Results: Furthermore, blood glucose levels measurement showed no significant difference between groups compared with negative control, which was $p > 0.05$. The stomach of groups that treated with metformin and bitter melon fruit juice histopathologically showed no significant differences.

Conclusion: The use of bitter melon once daily together with metformin is a better choice, while twice daily might induce hypoglycemia and mice death. There is no interaction between them on lowering blood glucose.

Keywords: metformin, *Momordica charantia*, diabetes mellitus

DDC 616.99419

Purnomo A, Bintoro UY, Sedana MP, Ashariati A (Hematology Oncology Medic Sub-specialist Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, Indonesia)

Association between Hasford Scoring System and Hematologic Response in Chronic and Accelerated Phase of Chronic Myelocytic Leukemia Patient with Imatinib for Three Months

Mol Cell Biomed Sci. 2019; 3(2): 88-94

Abstract (English)

Background: Hasford score is a scoring system which was made in interferon treatment era to assess chronic myelocytic leukemia (CML) prognosis. Complete hematologic response (CHR) is the milestone of prognosis evaluation. CHR achievement will significantly increase survival. Imatinib is a revolutionized treatment that change the prognosis of CML. With the advent of Imatinib, lessened the prognostic impact of the Hasford score to predict prognosis.

Materials and Methods: An observational analytic with prospective cohort study conducted in oncology outward division Dr. Soetomo hospital Surabaya, from July until October 2018. Hasford score determined in 32 patients at the beginning of the study, given imatinib and followed up regularly for 3 months to know the hematologic response. Data were analyzed using Fisher exact test which was considered significant if $p < 0.05$.

Results: Median age was 39 years old, male 37.5% and female 62.5%, the median spleen was 18 cm, median hemoglobin was 9.1 g/dL, median leukocyte was $180 \times 10^9/L$, median thrombocyte was $645 \times 10^9/L$, median eosinophil was 2.9%, median basophil was 4.6%, median myeloblast was 6%. Hasford score showed 3.1% in low risk, 25% in intermediate risk and 71.9% in high risk. As much as 78.1% complete hematologic response was found in patient, and 21.9% was incomplete.

Conclusion: There was no association between Hasford scoring system and hematologic response in chronic and accelerated phase of chronic myelocytic leukemia patient with imatinib for three month. Hasford score had no impact in hematologic response with imatinib.

Keywords: Hasford score, hematologic response, CML, imatinib

Molecular and Cellular Biomedical Sciences

DDC 571.978

Saragih CF, Rivany R, Sahil MF, Fadjrir, Ardiansyah E, Yaznil MR, Sarirah M (Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia)

The Difference of Bax Protein Expression between Endometrioma and Ovarian Carcinoma

Mol Cell Biomed Sci. 2019; 3(1): 95-9

Abstract (English)

Background: Endometriosis is a benign disease that has malignant properties such as genetic polymorphism, loss control of cell proliferation, infiltration, and local spread or to distant places. Several endometriosis studies linking endometrioma/ovarian endometriosis with an increased risk of ovarian malignancy give rise to a transformation phenomenon of endometriotic cysts into malignancy. Bax is a pro apoptotic protein whose expression decreases in a malignancy. This decrease is related to the poor prognosis of endometrioma and ovarian carcinoma. This study was aimed to identify the expression and the difference of Bax expression between endometrioma and ovarian carcinoma.

Materials and Methods: Fifty of paraffin blocks of endometrioma tissue and ovarian carcinoma (serous, mucinous, clear cell, and endometrioid type) were examined by immunohistochemical using Bondmax Full Automatic with specific monoclonal antibody to identify Bax expression. The difference of Bax expression score between endometrioma tissue and ovarian carcinoma was tested by Mann-Whitney test with significant value was set at $p < 0.05$.

Results: This study found that mean Bax expression score in endometrioma tissue and ovarian carcinoma was 3.88 and 3.72. No difference of Bax expression between endometrioma tissue and ovarian carcinoma ($p > 0.05$). No difference of Bax expression between the clinical stages and histopathological types of ovarian carcinoma ($p > 0.05$).

Conclusion: There are no statistically significant difference in Bax protein expression in ovarian cancer and endometrioma.

Keywords: Bax expression, endometrioma, ovarian carcinoma, apoptotic resistance

DDC 613.286

Sugianto M, Achadiyani, Nugraha GI (Postgraduate Program of Antiaging and Aesthetics Medicine, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia)

Antioxidant Effects of Red Fruit Oil on MMP-1 Gene Expression and Malondialdehyde Levels on Skin Exposed to UVB Rays

Mol Cell Biomed Sci. 2019; 3(2): 100-6

Abstract (English)

Background: Chronic exposure ultraviolet (UV)-B radiation causes reactive oxygen species (ROS) formation. Furthermore, ROS will induce the formation of malondialdehyde and increase matrix metalloproteinase (MMP)-1 expression. One strategy against the free radicals effects is by consuming antioxidants. This study aims to analyze the antioxidants effect of red fruit oil (RFO) on MMP-1 expression and malondialdehyde levels due to exposure to UVB rays.

Materials and Methods: Thirty male Wistar rats were divided into 5 groups. The P0 group was not given treatment, the P1 group was only exposed to UVB light, the P2 group was exposed to UVB light and given 0.5 mL/200 g body weight (BW) of RFO, the P3 group was exposed to UVB light and given 1 mL/200 g BW of RFO, and group P4 exposed to UVB rays and given 2 mL/200 g BW of RFO. Experimental animals would be examined for MMP-1 expression and malondialdehyde level. RFO would be identified with β -carotene and tocopherol content.

Results: Beta-carotene and tocopherol were detected in RFO. RFO reduced significantly MMP-1 expression ($p < 0.05$) in P2 group (0.73 \pm 1.27), P3 group (0.63 \pm 0.95), P4 group (9.56 \pm 20.97) compared group P1 (48.07 \pm 65.58). However, RFO did not reduce malondialdehyde levels ($p > 0.05$).

Conclusion: Our research demonstrates RFO containing tocopherol and β -carotene can reduce the MMP-1 expression, but does not affect malondialdehyde levels due to exposure to UVB rays. An effective dose that can reduce malondialdehyde levels and MMP-1 expression is 1 mL/200 g BW.

Keywords: red fruit oil, antioxidant, skin, MMP-1 expression, malondialdehyde, UVB rays, photoaging

DDC 615.321

Sovia E, Anggraeny D (Pharmacology Laboratory, Faculty of Medicine, Universitas Jenderal Achmad Yani, Cimahi, Indonesia)

Sugar Palm Fruits (*Arenga pinnata*) as Potential Analgesics and Anti-Inflammatory Agent

Mol Cell Biomed Sci. 2019; 3(2): 107-14

Abstract (English)

Background: Sugar palm fruit (*Arenga pinnata*) is used for osteoarthritis empirically. It also has antioxidant activity and showed inhibition to lipoyxygenase activity. The study about analgesic and anti-inflammatory activities of sugar palm fruit is still limited, this study was initiated to explore analgesic and anti-inflammatory effects of sugar palm fruit ethanol extract (SFEE).

Molecular and Cellular Biomedical Sciences

Materials and Methods: Acetic acid induced writhing was performed for screening analgesic activity, meanwhile anti-inflammatory activity was tested against rat paw edema. Acute toxicity and phytochemical screening were also investigated.

Results: The results of phytochemical screening revealed that flavonoids, alkaloids and quinones were present in SFEE. SFEE 50 and 100 mg/kg have analgesic effect and show the anti-oedematogenic effect against paw edema induced by carrageenan. SFEE could significantly decrease the neutrophils numbers as compared to the carrageenan-treated group. Neutrophil activation has been shown to contribute to tissue inflammation and damage.

Conclusion: SFEE have analgetic and anti-inflammatory activity.

Keywords: *Arenga pinnata*, analgesic, anti-inflammatory, acute toxicity

DDC 615.321

Sudiono J, Hardina M (Department of Oral Pathology, Faculty of Dentistry, Universitas Trisakti, Jakarta, Indonesia)

The Effect of *Myrmecodia pendans* Ethanol Extract on Inflamed Pulp: Study on Sprague Dawley Rats

Mol Cell Biomed Sci. 2019; 3(2): 115-21

Abstract (English)

Background: Inflammation is a body response caused by injury and infection. Pulpitis is a pulp tissue inflammation which is the continuous process of pulp hyperemia by bacteria invasion. *Myrmecodia pendans* or Sarang semut is known to contain flavonoid compound which has the anti inflammation effect. The purpose of this study is to investigate the effect of *Myrmecodia pendans* ethanol extract on the healing process of pulp inflammation.

Materials and Methods: This experimental study involved pre- and post-*in vivo* treatment of 27 Sprague Dawley rats in which the induced pulpitis model was obtained by injecting 0.01 mL *Porphyromonas gingivalis* into the dental pulp for 48 hours. Subjects were divided randomly into Group I (negative control), Group II (pulpitis treated by *Myrmecodia pendans* extract ethanol as treatment group), and Group III (pulpitis treated by Ca(OH)₂ as positive control group). Group II and III as pulpitis treatment groups were divided into subgroups based on the induction periods of 48 hours (2 days), 168 hours (7 days), and 366 hours (14 days). All specimens were processed into the slides and evaluated microscopically for the healing process.

Results: The result of this study showed significant difference ($p < 0.05$) among groups on day 2, 4 and 7. On day 4, the pulpitis treatment group of *Myrmecodia pendans* extract showed better healing process than Ca(OH)₂. On day 7, the pulpitis treatment group of Ca(OH)₂ showed better healing process than *Myrmecodia pendans* extract. On day 14, both of the pulpitis treatment groups showed normal pulp.

Conclusion: *Myrmecodia pendans* ethanol extract is effective for the healing process of inflamed pulp.

Keywords: inflamed pulp, *Myrmecodia pendans*, sarang semut, Ca(OH)₂, healing process

DDC 615.321

Girsang E, Lister INE, Ginting CN, Khu A, Samin B, Widowati W, Wibowo S, Rizal (Universitas Prima Indonesia, Medan, Indonesia)

Chemical Constituents of Snake Fruit (*Salacca zalacca* (Gaert.) Voss) Peel and *in silico* Anti-aging Analysis

Mol Cell Biomed Sci. 2019; 3(2): 122-8

Background: Skin aging is a condition where skin is unable to retain both its physiological and structural integrity. Plants is the main source of phytochemicals compound with wide range of biological activities. Through the efforts of ongoing scientific researches, an increasing number of plant extracts and phytochemicals have been showed promising result as anti-aging agent. Snake fruit (*Salacca zalacca* (Gaert.) Voss) is tropical plant belongs to the palm tree family (Arecaceae) that served as important crop in Indonesia. Despite its utilization, the phytochemical compound available in snake fruit, especially its peel have not been well documented. Present study aimed to elucidate the phytochemical constituent of snake fruit peel and its anti-aging potency.

Materials and Methods: Snake fruit peel extract (SPE) was subjected to qualitative phytochemical assay, high performance liquid chromatography, and molecular docking towards protein related in skin aging.

Results: The screening showed SPE contained phytochemical compound belong to flavonoid, tannin, phenol, triterpenoid, saponin and alkaloid. Thus, based on the analysis only chlorogenic acid was present in SPE whilst rutin and caffeic acid were not detected. The SPE was contained chlorogenic acid around 1.074 mg/g dry weight. Chlorogenic acid had the high binding affinity towards matrix metalloproteinase (MMP)-1 (-9.4 kcal/mol).

Conclusion: Current findings may provide scientific evidence for possible usage of SPE and its compounds as antioxidant and anti-aging agent.

Keywords: *Salacca zalacca*, phytochemical compound, high performance liquid chromatography, anti-aging



Molecular and Cellular Biomedical Sciences

Volume 3, Number 2, September 2019

Information of this journal can be accessed at: <https://CellBioPharm.com/ojs/index.php/MCBS>



Print ISSN: 2527-4384



Online ISSN: 2527-3442



REVIEW ARTICLE

MCBS

Mol Cell Biomed Sci. 2019; 3(2): 60-6
DOI: 10.21705/mcbs.v3i2.66**Adiponectin and Its Role in Inflammatory Process of Obesity**Ami Febriza^{1,2}, Ridwan³, Suryani As'ad⁴, Vivien Novarina Kasim⁵, Hasta Handayani Idrus⁶¹Department of Physiology, Faculty of Medicine, Universitas Muhammadiyah Makassar, Makassar, Indonesia²Postgraduate Program of Medical Science, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia³Mappa Oudang Nursing Academy, Makassar, Indonesia⁴Department of Clinical Nutrition, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia⁵Faculty of Sport and Health, Universitas Negeri Gorontalo, Gorontalo, Indonesia⁶Department of Microbiology, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia

Obesity is a chronic, low degree systemic inflammatory status. Microarray examination shows a disturbance in the expression of cytokine, chemokine, complementary protein and half of the other acute phase components in obese patients. Adiponectin is the hormone that increases insulin sensitivity, while its level decreases under condition of fatty tissue enlargement that occurs in obesity. Excessive weight causes the adipocyte cells and adipose tissues produce various types of mediators. The inflammatory process is the main cause of metabolic diseases, and the main role of adipose tissue in the inflammatory process is determined by the production of pro-inflammatory mediators and anti-inflammatory mediators. Adiponectin has an important anti-inflammatory effect on obesity. Adiponectin works on macrophage and monocyte to inhibit the production of pro-inflammatory cytokine and increase the expression of interleukin (IL)-10 and IL-1 receptor antagonists. Adiponectin reduces induction of intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 endothelial adhesion by TNF- α or resistin. In obese patients, it is characterized by resistance to adiponectin alongside a decrease and the possibility of adiponectin loss in the receptor population in liver and muscles, leading to low adiponectin level.

Keywords: adiponectin, obesity, inflammation**Introduction**

Overweight and obese are disorder or disease characterized by excessive accumulation of fat tissue in the body.¹ Overweight is defined as having a body mass index (BMI) between 25 and 29.9, while obese is defined as having a BMI of 30 or higher. Overweight and obese people, who

are characterized by fat deposits, have experienced a chronic low-grade systemic inflammatory process. The results of microarray examination in obese patients indicate a disturbance in the expression of cytokine, chemokine, complementary protein and half of the other acute phase components. It has also been suggested that the theory that activation of non-specific immune system components

Date of submission: February 8, 2019
Last Revised: March 7, 2019
Accepted for publication: March 8, 2019

Corresponding Author:

Ami Febriza
Department of Physiology, Faculty of Medicine
Universitas Muhammadiyah Makassar
Gunung Sari, Rappocini, Makassar 90221, Indonesia
E-mail: amifebriza@med.unismuh.ac.id



Cell and
Biopharmaceutical
Institute



can be considered a factor that allows the development of obesity and inflammation associated with it. These mediators provide important systemic effects may lead to insulin resistance, metabolic disorder and cardiovascular disease in obese patients.²

Obesity pathomechanism is based on the theory of inflammation, which is characterized by lipid accumulation in adipose tissue and expansion of fat mass leading to the initiation of the inflammatory process. It starts with adipose cells producing pro-inflammatory cytokines and chemokine, including tumor necrosis factor (TNF)- α , interleukin (IL)-6, leptin, resistin, monocyte chemoattractant protein (MCP)-1, and plasminogen activator inhibitor (PAI)-1. Vascular endothelial cells respond through increased expression of adhesion molecules, which together with chemokine will attract immune cells, including monocyte-macrophages towards adipose tissue. Together, adipose cells, immune cells and endothelial cells and the resultant mediators will create an inflammatory environment that triggers insulin resistance. Pro-inflammatory mediators and proatherogenic mediators then enter the circulation, causing insulin resistance and increasing the risk of atherosclerosis.³

Adiponectin, an adipocytokine, has an important anti-inflammatory effect on obesity. In obese patients, it is characterized by resistance to adiponectin along with a decrease and the possibility of loss of adiponectin receptor population in liver and muscles, leading to low level of adiponectin. Adiponectin resistance occurs due to downregulation of adiponectin receptors (AdipoRs). Low level of adiponectin as anti-inflammatory will tend to aggravate the inflammatory process in obese people. Another report states that adiponectin is a key element at the molecular level that mediates the occurrence of insulin resistance in obese population.⁴

The study was conducted by Eizadi, *et al.*, in obese adult men, with an analysis using the Independent T test.⁵ The samples show lower adiponectin level in obese men compared to men with normal weight (5.44 ± 1.23 in the obese group and 7.56 ± 1.32 in the normal weight group, $p=0.021$). Based on research by Bacha, *et al.*, in obese adults, there is a decrease in adiponectin level at around 50% compared to adults of normal weight.⁶ In the obese adult group with more visceral fat tissues, they tend to have lower adiponectin level compared to obese people with less visceral fat tissues (6.2 ± 0.9 and 9.0 ± 1.0 $\mu\text{g/mL}$, $p=0.05$). This review intends to provide an explanation of the relationship and mechanism of adiponectin in the inflammatory process in obesity.

Adiponectin Molecules

Adiponectin is one of the adipocytokines that was first discovered in 1995 by Scherer. Adiponectin is also known as adipocyte complement related protein 30 kilodalton (ACRP 30), AdipoQ, adipose most abundant gene transcript (apM)-I and gelatin binding protein 28 kilodalton (GBP 28).⁷ Adiponectin has gene mapping on chromosome 3q27. Several analyzes of single nucleotide polymorphisms (SNPs) and missense mutations, it was found that adiponectin gene is associated with the metabolic syndrome.⁸

Adiponectin Structure

Adiponectin is a protein formed from 247 amino acids consisting of 4 parts, namely amino acid terminals, variable regions, collagenous domains (cAd) and globular carboxy/globular terminal C-terminal domains of adiponectin (gAd). Adiponectin includes a collagen superfamily that dissolves and has a homologous structure with collagen VIII and X factor, Clq complement factor and TNF family.⁹

X-ray crystallography from gAd reveals a homologous structure with TNF- α . This indicates a link between evolutionary development between TNF- α and adiponectin. Both of these components have the opposite function, namely TNF- α as proinflammatory and adiponectin as anti-inflammatory.⁷

The basic form of adiponectin is a trimer which is formed by three monomer bonds in the globular domain. The monomer structure is not found to be circulated but is retained in adipocytes. Four to six trimers form a higher structure called oligomers with plasma concentrations of 5-30 $\mu\text{g/L}$.⁷

Plasma level of adiponectin ranges from 3.0-30 $\mu\text{g/L}$, whereas adiponectin levels in cerebrospinal liquor is reported in 1-4% of serum level. Although it is not yet clear whether adiponectin can pass through the blood-brain barrier, there is evidence that mammalian adiponectin can. The half-life of adiponectin is approximately 14 hours.¹⁰

Yamauchi separates 2 adiponectin receptors, AdipoR1 and AdipoR2. Adipo R1 is produced more in skeletal muscles and AdipoR2 in the liver. AdipoR1 mediates the activation of peroxisome proliferators activator receptor (PPAR)- α , adenosin monophosphate activated proteinkinase (AMPK), glucose and β oxidation uptake, thus increasing gluconeogenesis. AdipoR2 is involved in the activation of PPAR nuclear receptors to mediate β oxidation and reception of reactive oxygen species (ROS).⁷

Two forms of receptors have been cloned for adiponectin with distinct distribution and affinity for the molecular form of protein. AdipoR1 is a receptor with high affinity for gAd, in contrast with full-length adiponectin (fAd), whilst AdipoR2 has intermediate affinity for both forms of adiponectin. AdipoR1 is expressed in skeletal muscle, while AdipoR2 is mainly expressed throughout the liver. Such finding is in line with observations that suggest that fAd has a greater effect on metabolic signals in the liver. Adiponectin may have an anti-tumor effect by acting as a negative regulator of angiogenesis by inducing endothelial cell apoptosis mediated by caspase. This effect is seen not to be affected by AMP-kinase intermediate signals. Besides, adiponectin has anti-inflammatory, anti-fibrotic effects on liver tissue, anti-diabetic and anti-lipidemic. AdipoR2 was found first in the liver, where AdipoR1 was reported to be found previously in skeletal muscles. Adiponectin level in plasma is significantly lower in obesity.¹¹

Adiponectin Secretion

Adiponectin is synthesized in white fat cell tissues (adipocytes) and is produced during fat cell differentiation. The results show that adipose tissues are not only a place for storing fat, but also are endocrine organs that play an important role in interaction with endocrine, metabolic and inflammatory signals to regulate the body's energy homeostasis.¹² Adiponectin was first discovered while examining gene expression in human's visceral and subcutaneous fat tissue, which was aimed to determine the mechanism of diseases associated with obesity. Unexpectedly, genes expressed in subcutaneous and visceral fat tissue, at 20% and 30%, are genes that produce various kinds of bioactive secretory proteins (bioactive secretory protein), which are then called adipocytokine. One of these adipocytokines is adiponectin.^{13,14}

Factors affecting Adiponectin Level

Gender influences the metabolic and endocrine function of adipose tissues. Women have a greater percentage of body fat than men. Increased adiposity in women is associated with larger fat cell size, increased lipolysis stimulation, increased triglyceride (TG) synthesis in this depot. This finding implies that female hormones play a significant role in these depot differences between genders, resulting in differences in adipocyte metabolism. Estrogen is a clear candidate and may mediate several differences in

adipocyte metabolism. Sexual dimorphism is also related to differences in the distribution of the adiponectin complex in circulation.^{15,16}

A cross-sectional study involving 705 men, 262 women in Japan, ages 30-65 years, BMI of 22.5 ± 2.9 kg/m². Serum adiponectin concentration was measured using enzyme-linked immunosorbent assay (ELISA) method. Serum adiponectin concentration obtained in women (13.5 ± 7.9 µg/L) was significantly higher than men (7.2 ± 4.6 µg/L).¹⁷ Adiponectin level is higher in women. It is assumed that influence of sexual hormone regulates adiponectin production.¹⁸

Factors that also affect plasma adiponectin level are including circadian rhythm, showing the regulation of diurnal and pulsatile adiponectin secretion in humans. Adiponectin level reaches their peak in the morning and declines at night.¹⁹ Other factors that affect the expression and secretion of adiponectin are dietary factors. Fish oil and linoleic acid are also able to increase plasma adiponectin level, which is in line with the fact that consumption of these substances will provide a protective effect on diabetes mellitus.²⁰ In contrast, diets with high carbohydrates and fats can reduce plasma adiponectin level.²¹ In addition, level of adiponectin plasma is negatively correlated with BMI, insulin resistance, TG, and low density lipoprotein (LDL) and is positively correlated with high density lipoprotein (HDL).¹⁷ High level of plasma adiponectin concentration were also found in thin individuals and patients with type 1 diabetes mellitus, and level is low in patients with type 2 diabetes mellitus and obese individuals.²²

Adiponectin as Anti Inflammation

The role of adiponectin and TNF- α inhibits the production of one another in adipose tissues. C-reactive protein (CRP) expression is negatively regulated by adiponectin in fat tissues. Adiponectin expression is suppressed by IL-6 in fat tissues. Adiponectin inhibits monocyte adhesion and TNF- α -induced adhesion molecular expression, macrophage transformation into foam cells, TNF- α expression in macrophage and smooth muscle cell proliferation.^{12,23}

Adiponectin can improve the negative impact of TNF- α on endothelial function. Without the need to inhibit the bonds of TNF- α and fAd, it can inhibit the adhesion molecules induced by TNF- α , VCAM-I, E-selectin and ICAM-I. Adiponectin suppresses inflammatory changes by inhibiting inhibitory nuclear factor kappa B (NF- κ B) phosphorylation and NF- κ B activation without affecting

activation of c-Jun N-terminal kinase (JNK), p38 and Akt which is activated by TNF- α . Adiponectin inhibits leukocyte colony formation, thus decreasing phagocytic activity and TNF- α secretion.²⁴

A Study reported that adiponectin inhibits cell proliferation induced by oxidized-LDL (oxLDL), inhibits superoxide secretion-induced, and activation of p42/p44 MAPK by oxLDL. The impact of circulating oxLDL on the vascular wall results in foam cell formation, inactivation of endothelial nitric oxide (eNo), induction of inflammatory responses and formation of ROS. All these components are known to play an active role in the atherogenesis process.²⁴

The Inflammatory Process induced by Changes in Adipose Tissues in Obesity

Obesity conditions are associated with chronic inflammation characterized by response to abnormal cytokine production and activation of inflammatory signaling pathways. Adipose tissues in obese patients are characterized by progressive inflammation and infiltration by macrophages. Changes in the size of adipocyte and fat cells cause physical changes in the surrounding area and modification of the paracrine function of adipocytes. In obesity, adipocyte cells will release low level of TNF- α , which can stimulate preadipocyte cells to produce chemoattractant, namely MCP-1. Similarly, endothelial cells also secrete MCP-1 in response to cytokines. Therefore, both preadipocytes and endothelial cells can be responsible for attracting macrophages to adipose tissues.²⁵

Adiposopathy is the accumulation of ectopic pathogenic adipocytes due to positive energy, sedentary, genetic, and environmental balance. The manifestation is a combination of adipocytes which are hypertrophy and ectopic, especially in the visceral. Such combination causes immunological and metabolic disorders.²⁶ Adipocytes have dramatically varying cell sizes. Cell diameter can be about ten times as large and its volume becomes a thousand times bigger. This size affects the level of inflammation, lipid mobilization, and the pattern of adipocyte secretion. The spread of adipocytes in the abdomen is called the Android obesity pattern and those around the hips and thighs are called gynoid obesity pattern. From several studies, it is known that the form of android often describes fat accumulation in visceral organs associated with metabolic disorders including dyslipidemia, hypertension, and glucose intolerance.²⁷

Adipose tissues in non-obese individuals consist of a number of inflammatory cells and secretes various

active substances; however, adipose tissues in obese individuals show more accumulation of macrophages and T cells, resulting in excessive amount of inflammatory mediators, such as MCP-1 and IL-6, and low adiponectin secretion. Increasingly large adipocyte cells will trigger stress in the endoplasmic reticulum (ER). Such condition is important in triggering inflammatory kinases, such as JNK and I-kappa-B kinase (IKK), which ultimately inhibit insulin signals and activate inflammatory cascades and inflammatory mediator production. The available evidence demonstrates that increased chemokine production, such as MCP-1 in obesity adipose tissues can increase the accumulation of macrophages. In tissues, monocytes and macrophages can be sources that secrete TNF- α . Cytokines, such as TNF- α and other stimuli, can lead to further activation of inflammatory kinases. Several studies have shown that T cells also accumulate in adipose tissues in obese individuals. Interferon-gamma (IFN γ), a typical T-helper 1 cytokine which possibly regulates the expression of TNF- α , MCP-1, and other inflammatory mediators, shows a role for adaptive immunity in the pathophysiology of obesity. Adipokines, such as IL-6, into the circulation can also trigger important systemic effects, such as increased production of acute inflammatory mediator in the liver and coagulation factors, which are likely to correlate with the incidence of atherothrombosis.²

Increased secretion of leptin (and/or decreased production of adiponectin) secreted by adipocyte cells can also cause accumulation of macrophages by stimulating transport of macrophages towards adipose tissues and will also increase adhesion of macrophages to vascular endothelial cells. Physical damage to the endothelium, caused both by size changes and oxidative damage due to the more lipolytic environment, plays a role in the recruitment and accumulation of macrophage, similar to those seen in atherosclerosis. Any initial stimulus attracts macrophages into adipose tissue, but once these macrophage cells have infiltrated adipose tissue and become active, the macrophages together with adipocyte cells and other cell types will form a vicious circle of accumulation of larger withdrawal of macrophages, inflammatory production cytokines, and cause impaired adipocyte cell function.²⁵

Adipogenesis is the process by which precursor cells (preadipocytes) diffuse into mature adipocytes. During diffusion, there are morphological changes, cell development, fat accumulation, changes in insulin sensitivity, and adipokine expression.²⁸ This mass

enlargement of adipocyte is a compensation for the insulin defect. Each adipocyte mass has a specific expression of the gene and responds differently to food, hormones, and temperature. Metabolically, active adipocytes found in the intra-abdominal, intra-muscular, perivascular and epicardial serve to provide energy for vital organs, such as liver, heart, blood vessels, and muscular muscles. However, the adipocytes in the omentum serve as sensors to regulate the diets eaten and distribute them from liver to the body through the mediation of autonomic neurons.²⁹

Apart from its anatomical location, the main difference between visceral and subcutaneous adipocytes is found in anabolic response, efficiency, proliferation, and *in vitro* differentiation. In mammals, adipocytes consist of 2 types, which are white adipose tissue (WAT) and brown adipose tissue (BAT). WAT and BAT are divided on the basis of metabolic characteristics. WAT mainly serves to store excess energy for subsequent needs, whilst BAT is an energy-wasting organ. In experimental mice, BAT plays an important role to prevent and reduce obesity through increased energy disposal and heat production. The role of BAT in humans is unclear, because the number has drastically reduced in newborns; whereas in adults, 1 BAT is compared to 100-200 WAT.³⁰

There are two forms of macrophages in adipocytes, *i.e.*, type M1 macrophage which serves to remove TNF- α , IL-6, and increase inflammation; whilst M2-type macrophage serves to release anti-inflammatory cytokine, such as IL-10 and repair tissues. Both of these macrophages decrease alongside the decrease in body weight.³¹ In some situations, macrophages can increase up to 40% in adipocytes. The mechanism of macrophage mobilization is unclear, possibly involving chemotactic molecular secretion, and one of them is the C-C motif chemokine ligand 2 (CCL2) known as MCP-1. CCL2 is the main C-C ligand of the chemokine receptor 2 (CCR2) motive.³² As a result of adipocyte enlargement, the blood flow decreases; and if it cannot be compensated for by angiogenesis, there will be a disruption of perfusion and triglyceride clusters, followed by hypoxia. Hypoxia will stimulate the expression of angiogenic transcription factors, decreasing the expression of adiponectin, and PPAR- δ . Then adipocyte releases low level of TNF- α and stimulates preadipocyte to produce MCP-1. MCP-1 secretion aims to respond to the secretion of cytokine, leptin, and/or decreased adiponectin secretion. All of these conditions can cause accumulation and increase in adhesion of macrophages to endothelial cells and adiposity.²⁵

TNF- α is the most important inflammatory mediator secreted by macrophages. TNF- α enhances the induction of other proinflammatory molecules, such as IL-6, IL-8, MCP-1, and IL-1.³³ Obstructing the development and differentiation of preadipocytes can be done by interfering with the insulin signal through a signaling mechanism of tyrosine phosphorylation, inhibiting serine phosphorylation, and down-regulation of several insulin signaling pathways. All of these conditions might result in insulin resistance, increase lipolysis, and decrease glucose uptake by adipocytes. The addition of anti TNF- α can inhibit inflammation in preadipocyte; and in adipocytes, dietary regulation in experimental animals can reduce MCP-1 and macrophages.^{33,34}

The biggest abnormality in visceral free fatty acid metabolism is the inability to suppress lipolysis due to hyperinsulinemia.³⁵ Free fatty acids in the tissues will stimulate the production of destructive metabolite and cause structural abnormalities, necrosis, systemic inflammation, and endoplasmic reticulum stress. The saturated fatty acid bond with the 4th-like receptor-like macrophage (TLR-4) will activate NF-kB and TNF- α .³⁶ Besides stimulating β -cell apoptosis, albumin increases expression of uncoupling protein (UCP)-2 and can further inhibit the production of adenosine triphosphate (ATP) needed for insulin secretion.³⁷

The Relationship between Adiponectin and Inflammatory Process in Obesity

Previous research. revealed two important findings: first, obesity and type 2 diabetes were associated with low plasma adiponectin concentration and showed that this hypoadiponectinemia was evident in various ethnic groups with clear differences with the tendency in the obese group, type diabetes 2, and atherosclerosis. Second, the result shows that plasma adiponectin concentration is more closely related to insulin sensitivity and insulinemia level in fasting individuals compared with adiposity and glycemic condition. It suggests that hypoadiponectinemia in people with obesity and type 2 diabetes is largely due to insulin resistance and/or hyperinsulinemia.²²

The results of other studies in Japanese individuals have shown that plasma adiponectin concentrations are negatively correlated with BMI and therefore the level is lower in obese subjects than thin subjects.³⁸⁻⁴⁰ These results indicate that plasma adiponectin concentration is inversely related to the percentage of body fat and similar condition is also found in various ethnic groups. Adiponectin is one

of the protein secreted by adipose. Despite being produced exclusively in white adipose tissue, adiponectin levels are low in obesity. This condition is also consistent with findings in mice, murine homologue of adiponectin, *adipoQ* which also experience down-regulation in obesity.⁴¹

Conclusion

Adiponectin is the hormone that increases insulin sensitivity and decreases levels in condition of fatty tissue enlargement occurred in obesity. Adiponectin has an important anti-inflammatory effect on obesity. Adiponectin works on macrophage and monocyte to inhibit the production of pro-inflammatory cytokine and increase the expression of IL-10 and IL-1 receptor antagonists. Adiponectin reduces induction of ICAM-1 and VCAM-1 endothelial adhesion by TNF- α or resistin. In obese patients, it is characterized by resistance to adiponectin together with a decrease and possible loss of adiponectin receptor population in the liver and muscles, leading to low adiponectin level. Low level of adiponectin as anti-inflammatory will tend to aggravate the inflammatory process in obese people. In contrast to adiponectin, leptin is a hormone released by adipocyte cells. If the amount of adipose tissue increases, adipocyte cells will produce more leptin; therefore the leptin concentration in plasma is positively associated with the mass of fatty tissues.

Acknowledgements

I am deeply indebted to my supervisor, Prof. dr. Suryani As'ad, M.Sc, Sp.GK(K), senior lecturer from Department of Clinical Nutrition, Universitas Hasanuddin, for a warm support, inspiration and thoughtful guidance in writing this article. I would like to thank to Universitas Muhammadiyah Makassar for giving such an enthusiasm and support in this process of writing.

References

1. Yussac MAA, Cahyadi A, Putri AC, Dewi AS, Khomaini A, Bardosono S, *et al.* Prevalensi obesitas pada anak usia 4-6 tahun dan hubungannya dengan asupan serta pola makan. *Maj Kedokt Indones.* 2007; 57(2): 47-53.
2. Rocha VZ, Folco EJ. Inflammatory concepts of obesity. *Int J Inflamm.* 2011; 2011: 529061. doi: 10.4061/2011/529061.
3. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. *Gastroenterology.* 2007; 132(6): 2169-80.
4. Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R. Molecular mechanism of insulin resistance and obesity. *Exp Biol Med.* 2003; 228(10): 1111-7.
5. Eizadi M, Khorshidi D, Doali H. Relationship between serum adiponectin with anthropometrical and lipid profile biochemical indexes in obese adult men. *Int Conf Environ Biomed Biotechnol.* 2011; 16: 70-3.
6. Fida Bacha M, Rola Saad M, Neslihan Gungor M, Silva A, Arslanian M. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and β -cell function. *Diabetes Care.* 2004; 27(2): 547-52.
7. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. *Endocr Rev.* 2009; 26(3): 439-51.
8. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. *Clin Sci.* 2006; 110(3): 267-78.
9. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. *J Clin Invest.* 2006; 116(7): 1784-92.
10. Peterlin BL, Bigal ME, Tepper SJ, Urakaze M, Sheftell FD, Rapoport AM. Migraine and adiponectin: is there a connection? *Cephalalgia.* 2007; 27(5): 435-46.
11. Manju Chandran M, Susan A, Phillips M, Theodore Ciaraldi P, Robert R, Henry M. Adiponectin: more than just another fat cell hormone? *Diabetes Care.* 2003; 26(8): 2442-50.
12. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. *Arterioscler Thromb Vasc Biol.* 2004; 24(1): 29-33.
13. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor- α expression. *Diabetes.* 2003; 52(7): 1779-85.
14. Ntambi JM, Kim Y. Adipocyte differentiation and gene expression. *J Nutr.* 2000; 130(12): 3122-6.
15. Al-hashem F, Ibrahim I, Bastawy N, Rateb M, Haidara M, Dallak M, *et al.* Effect of insulin on adiponectin and adiponectin receptor-1 expression in rats with streptozotocin-induced type 2 diabetes. *J Health Sci.* 2011; 57(4): 334-40.
16. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. *Clin Endocrinol.* 2006; 64(4): 355-65.
17. Yamamoto Y, Hirose H, Saito I, Tomita M. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and independent of body mass index, in the Japanese population. *Clin Sci.* 2002; 103(2): 137-42.
18. Xu A, Chan KW, Hoo RLC, Wang Y, Tan KCB, Zhang J, *et al.* Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. *J Biol Chem.* 2005; 280(18): 18073-80.
19. Gavrilu A, Peng C, Chan JL, Mietus JE, Goldberger ARYL, Mantzoros CS, *et al.* Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. *J Clin Endocrinol Metab.* 2003; 88(6): 2838-43.
20. Nagao K, Inoue N, Wang YM, Yanagita T. Conjugated linoleic acid enhances plasma adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty (fa/fa) rats. *Biochem Biophys Res Commun.* 2003; 310(2): 562-6.
21. Pischon T, Girman CJ, Rifai N, Hotamisligil GS, Rimm EB. Association between dietary factors and plasma adiponectin concentrations in men 1 – 3. *Am J Clin Nutr.* 2005; 81 (4): 780-6.
22. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, *et al.* Hypoadiponectinemia in obesity and type 2 diabetes: close

- association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab.* 2001; 86(5): 1930-5.
23. Ouchi N, Walsh K. A novel role for adiponectin in the regulation of inflammation. *Arterioscler Thromb Vasc Biol.* 2008; 28(7): 1219-21.
 24. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. *J Clin Endocrinol Metab.* 2004; 89(6): 2563-8.
 25. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. *J Clin Invest.* 2003; 112(12): 1785-8.
 26. Bays HE, González-Campoy JM, Henry RR, Bergman DA, Kitabchi AE, Schorr AB, et al. Is adiposopathy (sick fat) an endocrine disease? *Int J Clin Pract.* 2008; 62(10): 1474-83.
 27. Kissebah AH, Krakower GR. Regional adiposity and morbidity. *Physiol Rev.* 1994; 74(4): 761-811.
 28. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. *Genes Dev.* 2002; 16(1): 22-6.
 29. Kreier F, Kap YS, Mettenleiter TC, van Heijningen C, van der Vliet J, Kalsbeek A, et al. Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. *Endocrinology.* 2006; 147(3): 1140-7.
 30. Oberkofler H, Dallinger G, Liu YM, Hell E, Krempler F, Patsch W. Uncoupling protein gene: quantification of expression levels in adipose tissues of obese and non-obese humans. *J Lipid Res.* 1997; 38(10): 2125-33.
 31. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J Clin Invest.* 2007; 117(1): 175-84.
 32. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. *Circ Res.* 2004; 95(9): 858-66.
 33. Lacasa D, Taleb S, Keophiphath M, Miranville A, Clement K. Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. *Endocrinology.* 2007; 148(2): 868-77.
 34. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *J Clin Invest.* 2006; 116(6): 1494-505.
 35. Jensen MD, Caruso M, Heiling V, Miles JM. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. *Diabetes.* 1989; 38(12): 1595-601.
 36. Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S, et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. *Arterioscler Thromb Vasc Biol.* 2007; 27(1): 84-91.
 37. Zhou H, Zhao J, Zhang X. Inhibition of uncoupling protein 2 by genipin reduces insulin-stimulated glucose uptake in 3T3-L1 adipocytes. *Arch Biochem Biophys.* 2009; 486(1): 88-93.
 38. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. *Circulation.* 1999; 100(25): 2473-6.
 39. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun.* 1999; 257(1): 79-83.
 40. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol.* 2000; 20(6): 1595-9.
 41. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. *J Biol Chem.* 1996; 271(18): 10697-703.